Public COA audit
Tirzepatide
Audited September 5, 2026
Several fields check out, but we found issues worth reviewing before you rely on this document.
- Legitimacy
- 92
- Confidence
- 88%
- Panels
- 2/7
- Purity (printed)
- 99.7%
Scored high because the document is mostly consistent but carries soft concerns, limited panel coverage (2/7), and 1 soft concern. To improve: include identity, purity, and endotoxin at minimum.
Document details
Fields extracted from the certificate — not order or payment data.
- Batch / lot
- WL-TR10-P00519
- Identity method
- FTIR (USP <197A>)
- Sample date
- 2026-06-08
- Issue date
- 2026-06-12
Original certificate
Embedded copy of the stored COA PDF or image. Download it for your records — PeptIQ’s audit is separate from the lab document itself.
7-panel checklist
Had data + good, had data + bad, reported without pass/fail, or missing. Missing lowers thoroughness — you decide whether that panel matters; PeptIQ’s score still factors coverage.
2 of 7 present · 2 passed · 0 failed · 0 reported · 5 missing
Missing is a thoroughness gap — not automatically bad. PeptIQ’s legitimacy score still weighs panel coverage; you can down-weight panels that don’t matter for your use case.
Identity
Tested · passed · core
Compound identity confirmed (e.g. HPLC, mass spec).
FTIR sample spectrum confirms the presence of Tirzepatide with addition of excipient(s)/fillers
Purity
Tested · passed · core
Reported purity percentage for the analyte.
99.7%
Heavy metals
Not on this certificate file
Lead, arsenic, cadmium, mercury, or similar limits.
No evidence on this file. Vendors sometimes publish separate purity and endotoxin reports for the same lot — check the brand page before treating this as “never tested.”
Microbial
Not on this certificate file
Bioburden / microbial limits testing.
No evidence on this file. Vendors sometimes publish separate purity and endotoxin reports for the same lot — check the brand page before treating this as “never tested.”
Endotoxin
Not on this certificate file · core
LAL or chromogenic endotoxin assay.
No evidence on this file. Vendors sometimes publish separate purity and endotoxin reports for the same lot — check the brand page before treating this as “never tested.”
Sterility
Not on this certificate file
Sterility testing where applicable.
No evidence on this file. Vendors sometimes publish separate purity and endotoxin reports for the same lot — check the brand page before treating this as “never tested.”
Residual solvent / water
Not on this certificate file
Residual solvents or water content limits.
No evidence on this file. Vendors sometimes publish separate purity and endotoxin reports for the same lot — check the brand page before treating this as “never tested.”
How to read this
Had data · good
Panel present with a pass (or clear acceptance).
Had data · bad
Panel present with a fail — a concrete quality signal.
Had data · unclear
Value reported without an explicit pass/fail mark.
Missing on this file
Not on this certificate file. Lowers file thoroughness; a sibling endotoxin/purity report for the same lot may still exist. PeptIQ’s score still factors coverage.
Findings
Evidence-linked observations from this audit.
High HPLC purity
99.7% purity by HPLC (USP <621>) meets specification of ≥98%. This is normal for research-grade peptides.
Identity confirmed
FTIR spectroscopy confirms Tirzepatide presence with excipients/fillers, consistent with formulated peptide product.
Batch information complete
Lot number WL-TR10-P00519, BT Sample ID 005000040403812, customer Lumira, manufacturer Lumira.
Dates valid
Date tested 2026-06-08, issue date 2026-06-12. Both dates are on or before 2026-09-05 and are valid.
Lab information present
BTLabs, West Palm Beach FL, with contact info and website https://btlabtesting.com. QR code present for verification.
Limited scope report
This COA explicitly states it does NOT provide information on particulate matter, microbial contamination, or endotoxins. This is a purity/identity-focused report. Missing panels: heavy metals, microbial, endotoxin, sterility, residual solvents/water.
Professional presentation
Report includes FTIR spectrum, HPLC chromatogram, potency assay (10.5 mg, 105.1% of label claim), peptide-to-excipient ratio (1:4.3), dual scientist signatures, and proper USP method references.
PeptIQ COA reports analyze document content and publicly verifiable lab signals. They are educational and not a guarantee of product quality, legality, or safety. Always consult a qualified professional before making health decisions. We never publish purchase prices, shipping details, or uploader identity.